Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies

26 Apr 2020

Abstract excerpt

Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a progressive motor disease with no broadly effective treatment. However, most current therapies are based on symptoms rather than the underlying disease mechanisms. In this review, we describe potential therapeutic strategies based on known pathological biomarkers and related pathogenic processes. The three major conclusions from the current...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Genetic Neurodegenerative Diseases
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32357546
DOI: 10.3390/ijms21093063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic StrategiesPMID 32357546Read ↗

Pharmacological Therapies for Machado-Joseph Disease.Semantic proximity Read ↗

Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapySemantic proximity Read ↗

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to TherapeuticsSemantic proximity Read ↗

Recent therapeutic prospects for Machado–Joseph diseaseSemantic proximity Read ↗

Spermidine for the treatment of Machado-Joseph disease: induction of autophagy but also apoptosis?Semantic proximity Read ↗

n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.Semantic proximity Read ↗

Mitochondrial dysfunction in Machado Joseph Disease: insights from a multi-model systemSemantic proximity Read ↗

Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1.Semantic proximity Read ↗

Combined therapy with m-TOR-dependent and -independent autophagy inducers causes neurotoxicity in a mouse model of Machado–Joseph diseaseSemantic proximity Read ↗

Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathwaySemantic proximity Read ↗

Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3Semantic proximity Read ↗

Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado–Joseph disease modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.